Treatment of inflammatory bowel disease with 5-aminosalicylic acid (5-ASA) preparations during pregnancy is associated with an increased risk of stillbirth and preterm birth, but not congenital malformations, according to a report published in the February 1st issue of Gut.
Dr. B. Norgard, from Aarhus University Hospital in Denmark, and colleagues determined the effects of maternal 5-ASA treatment by analyzing data from 148 pregnancies exposed to such drugs and from 19,418 unexposed pregnancies. The exposed group included 60 pregnancies with prenatal or first trimester exposure only and 88 with exposure during the entire pregnancy.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!